repaglinide has been researched along with chitosan in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, MM; Vaghani, SS | 1 |
| Barzegar Jalali, M; Ebrahimi, HA; Hamidi, M; Javadzadeh, Y | 1 |
| Abo-Elseoud, WS; Basha, M; Fadel, SM; Hassan, EA; Hassan, ML; Sabaa, MW | 1 |
| Hamidi, M; Karami, Z; Nasihatsheno, N; Saghatchi Zanjani, MR | 1 |
4 other study(ies) available for repaglinide and chitosan
| Article | Year |
|---|---|
Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide.
Topics: Adhesiveness; Animals; Calorimetry, Differential Scanning; Carbamates; Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; Crystallography, X-Ray; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Compounding; Gastric Juice; Glutaral; Hydrogels; Hydrogen-Ion Concentration; Hypoglycemic Agents; Kinetics; Microscopy, Electron, Scanning; Piperidines; Povidone; Powder Diffraction; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Technology, Pharmaceutical; Wettability | 2011 |
Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
Topics: Administration, Intravenous; Animals; Blood Glucose; Carbamates; Cell Line; Cell Survival; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Fibroblasts; Hydrogels; Hypoglycemic Agents; Lipids; Male; Mice; Nanotechnology; Particle Size; Piperidines; Polyphosphates; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; Static Electricity; Surface Properties; Technology, Pharmaceutical | 2016 |
Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide.
Topics: Carbamates; Cellulose; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Hydrolysis; Hyperglycemia; Nanocomposites; Nanoparticles; Piperidines; Spectroscopy, Fourier Transform Infrared | 2018 |
Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion.
Topics: Administration, Oral; Animals; Biological Availability; Carbamates; Chitosan; Drug Compounding; Drug Liberation; Emulsions; Gastrointestinal Absorption; Humans; Hypoglycemic Agents; Intracellular Fluid; Male; Nanocapsules; Piperidines; Poloxamer; Polysorbates; Rats, Sprague-Dawley; Solubility | 2020 |